Apriso Shortage: What Providers and Prescribers Need to Know in 2026

As a provider managing patients with ulcerative colitis, you've likely fielded calls from patients unable to fill their Apriso (Mesalamine extended-release capsule) prescriptions. While Apriso is not listed as a formal shortage by the FDA or ASHP, real-world access challenges persist — and understanding the current landscape is essential for maintaining treatment continuity.

This briefing covers the current availability picture, prescribing implications, cost and access considerations, and tools to help your patients find their medication.

Current Supply Status and Timeline

As of Q1 2026, neither brand-name Apriso nor generic Mesalamine ER (0.375 g capsules) appears on the FDA's active drug shortage list. Manufacturing by Salix Pharmaceuticals (Bausch Health) continues, and multiple generic manufacturers are producing Mesalamine ER capsules.

However, the availability picture at the pharmacy level tells a different story. Patient-reported access challenges have persisted through 2024–2026, driven by several factors:

• Pharmacy inventory shifts: Many retail chains have transitioned entirely to generic Mesalamine ER, eliminating brand-name Apriso from their formularies. Patients with brand-specific prescriptions or insurance requirements encounter stock-outs.
• Automated inventory management: Chain pharmacy systems allocate shelf space based on dispensing volume. Low-volume specialty medications like Apriso are deprioritized, particularly at locations with smaller GI patient populations.
• Distribution regionalization: Wholesale distribution patterns can create pockets of limited availability even when national supply is adequate.

Prescribing Implications

The access landscape has several practical implications for prescribers:

Generic Substitution

Unless clinically contraindicated, prescribing generic Mesalamine ER rather than brand-name Apriso significantly improves your patient's ability to fill the prescription. Generic Mesalamine ER (0.375 g) is therapeutically equivalent (FDA AB-rated) and available from multiple manufacturers.

When writing prescriptions, consider:

• Allowing generic substitution (avoid "DAW" or "Brand Medically Necessary" unless truly warranted)
• Using the generic name "Mesalamine ER" to maximize pharmacy flexibility
• Noting the specific formulation (0.375 g extended-release capsule, quantity 120, once daily) to avoid confusion with other Mesalamine products

Formulary and Prior Authorization Awareness

Many commercial and Medicare Part D plans have implemented tiered access for Mesalamine products:

• Generic Mesalamine ER: Typically Tier 1-2, no prior authorization required
• Brand-name Apriso: Often Tier 3 or non-preferred, may require prior authorization or step therapy
• Alternative Mesalamine brands (Lialda, Pentasa, Delzicol): Coverage varies; some plans prefer one formulation over others

Proactively checking your patient's formulary before prescribing can prevent delays and reduce the number of pharmacy call-backs requesting alternative agents.

When to Consider Alternative Mesalamine Formulations

If Mesalamine ER is genuinely unavailable for a patient, the following alternatives offer comparable efficacy for UC maintenance:

• Lialda (Mesalamine delayed-release, 1.2 g tablets): Once-daily dosing, approved for both induction and maintenance. May require different prior authorization.
• Pentasa (Mesalamine controlled-release, 250/500 mg capsules): Four-times-daily dosing, releases throughout the GI tract. Useful when small intestinal involvement is suspected.
• Delzicol (Mesalamine delayed-release, 400 mg capsules): Three-times-daily dosing, targets terminal ileum and colon. Generic available.

When switching between Mesalamine formulations, note that the dosing regimen, total daily dose, and site of drug release differ. Counsel patients on the new schedule and monitor for symptom changes during the transition period.

For patient-facing alternative information: Alternatives to Apriso if you can't fill your prescription.

Cost and Access Landscape

Cost remains a significant barrier for many UC patients. Here's the current pricing picture:

• Brand-name Apriso (120 capsules): $500–$700/month cash price
• Generic Mesalamine ER (120 capsules): $42–$55/month with coupon card; ~$500 retail without coupon
• Salix Savings Card: Eligible commercially insured patients may pay as little as $0 for the first fill, $10 for subsequent fills (max $100 benefit per fill). Not valid for government insurance.
• Patient Assistance Programs: Bausch Health offers PAP for uninsured/underinsured patients. Third-party services like Prescription Hope offer access for approximately $50/month service fee.

For patients struggling with cost, recommend they explore coupon cards (SingleCare, GoodRx) for the generic, which can reduce out-of-pocket costs by over 90%.

Detailed patient savings guide: How to save money on Apriso in 2026.

Tools and Resources for Your Practice

Several tools can help streamline medication access for your UC patients:

Medfinder for Providers

Medfinder offers real-time pharmacy availability data that can help your clinical team identify which pharmacies currently have Mesalamine ER in stock. This reduces the cycle of rejected e-prescriptions and patient callbacks.

Consider:

• Checking Medfinder before sending prescriptions to confirm the receiving pharmacy has stock
• Sharing medfinder.com/providers with your nursing and MA staff as a resource
• Directing patients to medfinder.com when they report access issues

Pharmacy Communication Best Practices

• When e-prescribing, include a note indicating that generic substitution is acceptable (if appropriate)
• If a specific pharmacy is out of stock, offer to send the prescription to an alternative location the patient identifies
• For patients on mail-order pharmacy plans, proactively writing 90-day supply prescriptions can reduce stock-out risk

Drug Interaction Awareness

When co-prescribing with Mesalamine, keep these interactions in mind:

• Azathioprine / 6-Mercaptopurine: Mesalamine inhibits TPMT, potentially increasing thiopurine metabolite levels and toxicity risk. Monitor CBC closely.
• NSAIDs: Additive nephrotoxicity risk. Evaluate renal function if combination is necessary.
• Antacids: Specifically with Apriso/Mesalamine ER — antacids can alter the pH-dependent release mechanism. Counsel patients to avoid co-administration.

For comprehensive interaction data: Apriso drug interactions: what to avoid.

Looking Ahead

The Mesalamine market is mature, with multiple generic options available. The access challenges patients face are less about true supply shortages and more about the intersection of pharmacy economics, insurance formulary design, and patient awareness.

Providers can have the greatest impact by:

1. Prescribing generically when possible to maximize pharmacy flexibility
2. Proactively addressing cost concerns with patients and connecting them to savings resources
3. Using availability tools like Medfinder to route prescriptions to stocked pharmacies
4. Maintaining awareness of alternative Mesalamine formulations and their clinical considerations
5. Educating patients on the importance of early refills and backup pharmacy options

Final Thoughts

While Apriso is not in formal shortage, the practical reality for many UC patients is that finding their medication requires more effort than it should. As providers, we can bridge this gap through informed prescribing practices, patient education, and utilization of modern pharmacy-finding tools.

The goal is simple: keep patients on their maintenance therapy without interruption. With the right approach, that's achievable even in a challenging pharmacy landscape.

Share with your patients: Apriso shortage update: what patients need to know in 2026.

Provider medication access guide: How to help your patients find Apriso in stock.